Obagi announces success with solubilized acne medication
LONG BEACH, Calif. Obagi Medical Products, a developer of skin health products, announced today solubilized benzoyl peroxide for the treatment of acne may provide dramatic reductions in acne lesions within 4 weeks.
Tested at the Fall Clinical Dermatology Conference in Las Vegas, the results from a pooled analysis of three randomized, investigator-blind trials. In the analysis, reduction in inflammatory and non-inflammatory lesions was greater with the solubilized 5 percent BPO regimens than with the jar gel formulation of BPO/clindamycin. Additionally, patients reported greater overall satisfaction and comparable tolerability with the solubilized 5% BPO regimen.
The product, a novel patent pending formulation developed exclusively for Obagi Medical Products, is a 3-step acne system, which includes a pore therapy and cleanser, both of which contain 2 percent salicylic acid.
Patients reported high levels of satisfaction across all studies. Mean satisfaction scores in studies using the 3-part acne system were statistically significant following 1 week of treatment.
“The CLENZIderm M.D. acne treatment system offers to dermatologists and their patients an option that has been proven to be effective and well tolerated in multiple clinical trials,” said Dr. James Del Rosso, who presented the data at the conference. “There is solid science supporting both the technology itself and the therapeutic benefits of this system. Additionally, there are two formulations of the system available that can be tailored to the needs of the individual patient based on their skin type.”
Each treatment was applied once or twice daily for 2-4 weeks. Patients ranged from 11 to 45 years of age, with a mean age of 20 years, and were evaluated weekly. Patients were predominantly Caucasian with Fitzpatrick skin type III. Efficacy was based on a mean reduction in inflammatory and non-inflammatory lesion count. Tolerability was evaluated on severity of stinging/burning, erythema, dryness and itching.